The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid Treatment
This study has been completed.
Information provided by:
Tuen Mun Hospital
First received: September 5, 2006
Last updated: September 27, 2007
Last verified: September 2007
The efficacy of risedronate in prevention of bone loss in patients receiving high dose corticosteroid treatment
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
Primary Outcome Measures:
Secondary Outcome Measures:
- Adverse events, new vertebral fractures
| Estimated Enrollment:
| Study Start Date:
| Study Completion Date:
We compare the effect of risedronate with placebo in bone mineral density changes in patients receiving high dose corticosteroids for their underlying diseases
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with various medical conditions who require high dose glucocorticoid treatment: (1) pulse methylprednisolone; (2) oral prednisolone (>=0.8mg/kg/day) or equivalent for at least 6 weeks.
- Age>=18 years and <75 years.
- Pregnant or lactating women.
- Uncorrected hypocalcemia.
- History of esophageal stricture.
- Previous intolerance or hypersenstivity to biphosphonates.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00372372
|Tuen Mun Hospital
|Hong Kong, China |
Tuen Mun Hospital
||CC Mok, MD FRCP
||Tuen Mun Hospital, Hong Kong
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 5, 2006
||September 27, 2007
||Hong Kong: Ethics Committee
Keywords provided by Tuen Mun Hospital:
corticosteroids, bone mineral, risedronate, bisphosphonate
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on November 25, 2014
Bone Diseases, Metabolic
Bone Density Conservation Agents
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs